We intend to continue to move forward with diligence and urgency to generate the evidence necessary to bring SRP9001 to waiting Duchenne patients around the worldSarepta will host an investor webcast and conference call on Thursday Jan 7 2021 at 430 pm Eastern Time to discuss these results